BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
60.39
-1.03 (-1.68%)
Nov 20, 2026, 4:00 PM EST - Market closed
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $1.02B in the quarter ending September 30, 2026, with 32.02% growth. This brings the company's total for the last twelve months to $3.66B, up 18.14% year-over-year. In the year 2025, BioMarin Pharmaceutical had annual revenue of $3.22B with 12.87% growth. That makes BioMarin Pharmaceutical the 3,316th largest company in the world by revenue and 941st in the United States.
Revenue (ttm)
$3.66B
Revenue Growth
+18.14%
P/S Ratio
3.22
Revenue / Employee
$1,134,780
Employees
3,221
Market Cap
11.70B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full BioMarin Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.22B | 367.34M | 12.87% |
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | 1.70B | 212.84M | 14.27% |
| Dec 31, 2018 | 1.49B | 177.57M | 13.52% |
| Dec 31, 2017 | 1.31B | 196.79M | 17.62% |
| Dec 31, 2016 | 1.12B | 226.96M | 25.50% |
| Dec 31, 2015 | 889.90M | 140.61M | 18.77% |
| Dec 31, 2014 | 749.28M | 200.80M | 36.61% |
| Dec 31, 2013 | 548.49M | 47.76M | 9.54% |
| Dec 31, 2012 | 500.72M | 59.37M | 13.45% |
| Dec 31, 2011 | 441.36M | 65.09M | 17.30% |
| Dec 31, 2010 | 376.27M | 51.61M | 15.90% |
| Dec 31, 2009 | 324.66M | 28.16M | 9.50% |
| Dec 31, 2008 | 296.49M | 172.82M | 139.74% |
| Dec 31, 2007 | 123.67M | 39.46M | 46.86% |
| Dec 31, 2006 | 84.21M | 58.54M | 228.06% |
| Dec 31, 2005 | 25.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.72B |
| Exelixis | 2.50B |
| Halozyme Therapeutics | 1.80B |
| Madrigal Pharmaceuticals | 1.43B |
| Bio-Techne | 1.23B |
| BridgeBio Pharma | 945.54M |
| TG Therapeutics | 897.76M |
| Krystal Biotech | 470.03M |
BMRN News
- 3 days ago - BioMarin Pharmaceutical Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - BioMarin Pharmaceutical Slides: Jefferies Global Healthcare Conference - Filings
- 4 days ago - BioMarin Pharmaceutical Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 7 days ago - BioMarin price target lowered to $103 from $119 at Morgan Stanley - TheFly
- 9 days ago - BioMarin Pharmaceutical Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 16 days ago - BioMarin to Participate in Upcoming Investor Conferences - PRNewsWire
- 16 days ago - BioMarin price target lowered to $86 from $87 at JPMorgan - TheFly
- 17 days ago - BioMarin price target lowered to $60 from $62 at RBC Capital - TheFly